Home » Business News » 2013 » April » April 23, 2013

Pre-clinical results on naproxcinod in models of muscular dystrophy presented at MDA Scientific Conference

April 23, 2013 - Sophia Antipolis, France

Nicox S.A. (EURONEXT PARIS: COX)today announced promising pre-clinicalresults on naproxcinod, a CINOD (Cyclooxygenase-Inhibiting NitricOxide-Donating) anti-inflammatory candidate, in models of musculardystrophies. Thedata were presented by Nicox and the Center for Genetic MedicineResearch(1), acenter within the Children's Research Institute, Children's NationalMedicalCenter, in a poster session on April 22(nd) at the Muscular DystrophyAssociation (MDA) Scientific Conference in Washington, DC.

The research study data were presented in a poster entitled "Long-termtreatmentwith naproxcinod significantly improves skeletal and cardiac diseasephenotypein mdx mouse model of dystrophy" (poster #175). In this study, the effectsofnaproxcinod were investigated on skeletal and cardiac muscle function inmdxmice. Three doses of naproxcinod (10, 21 and 41 mg/kg) were given orally to4-week-old mdx mice (a reference model for Duchenne Muscular Dystrophy,DMD) for9 months and compared to 0.9 mg/kg of prednisolone. The results of thestudysuggest that naproxcinod may have potential as a safe therapeutic optionfor thetreatment of muscular dystrophies. Naproxcinod treatment at 10 and 21mg/kgresulted in significant improvements in hind limb grip strength as well asanapproximately 25-30% decrease in inflammation in fore and hind limbsmeasured byin vivo optical imaging. Furthermore, there were significant improvementsinheart function as evidenced by improved fraction shortening and ejectionfraction, measured using echocardiography, along with improvements insystolicblood pressure. In addition, the long term detrimental effects ofprednisolonetypically seen in skeletal and heart function were not observed at theeffectivedoses of naproxcinod.

Naproxcinod is a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating)anti-inflammatory candidate originally developed by Nicox for the relief ofthe signsand symptoms of osteoarthritis. The results presented on April 22(nd) 2013werefrom an exploratory research study sponsored by Nicox and conducted at theCenter for Genetic Medicine Research(1). The objective was to investigatethepotential for the use of naproxcinod in Duchenne Muscular Dystrophy (DMD)asthere is evidence that nitric oxide can play a critical role in thefunctioningof skeletal muscle.

The Nicox's current strategy is to evaluate the opportunity toout-licencenaproxcinod for the treatment of the signs and symptoms of osteoarthritisof theknee. Separately, the Company is also seeking specialized partners in thefieldof rare diseases who would be able to undertake and fund the potentialdevelopment of naproxcinod in Muscular Dystrophy. This approach is aimed atmaximising the opportunities to progress the development of naproxcinod inoneof these indications.

About muscular dystrophies:

Muscular dystrophies are a group of inherited diseases that cause muscleweakness and muscle loss. These diseases are due to defects in muscleproteins,leading to structure alteration and continuous damage of fibers duringcontraction. DMD is the most common and serious form of Muscular Dystrophy,withthe onset of symptoms occurring in early childhood (usually between threeandfive years of age) and primarily affects boys. This progressive conditionworsens throughout childhood, with patients becomingwheelchair-bound betweenthe ages of seven and thirteen. Most DMD patients die by the age of 20,mostfrequently as a direct result of respiratory/cardiac failure.

(1)The Center for Genetic Medicine Research (GenMed) is a center within theChildren's Research Institute, at Children's National Medical Center, inWashington DC. The Center is dedicated to translational research inmusculardystrophy. Founded in 1999, GenMed serves as the Department of IntegrativeSystems Biology (ISB) at the George Washington University School ofMedicine andHealth Sciences. The muscle disease research group is among the largestworldwide, and includes drug development, pre-clinical, and clinicalresearchgroups. GenMed has 50 faculty members and about 170 staff.

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-sizedinternational player in the ophthalmic market by building a diversifiedportfolio of innovative therapies and diagnostic tools. With a heritage ofscientific, business development and commercial expertise, the Nicox teamisfocused on developing and marketing novel pharmaceuticals and diagnosticdevicesthat can help people to enhance their sight. In the United States, NicoxmarketsAdenoPlus™, a test for the differential diagnosis of acuteconjunctivitisin-licensed from RPS®.

The Company's pipeline includes latanoprostene bunod, a noveldrug-candidatebased on Nicox's proprietary nitric oxide (NO)-donating R&D platform,developedin collaboration with Bausch + Lomb for the potential treatment of glaucomaandocular hypertension. Further NO-donating compounds are under development innon-ophthalmic indications, notably through partners, including Merck(known as MSDoutside the United States and Canada).

Nicox S.A. is headquartered in France and is listed on Euronext Paris(Compartment B: Small Caps). For more information please

This press release contains certain forward-looking statements. AlthoughtheCompany believes its expectations are based on reasonable assumptions,theseforward-looking statements are subject to numerous risks and uncertainties,which could cause actual results to differ materially from thoseanticipated inthe forward-looking statements.Risks factors which are likely to have a material effect on Nicox'sbusiness arepresented in the 4th chapter of the « Document de référence,rapport financierannuel et rapport de gestion 2012 » filed with the FrenchAutorité des MarchésFinanciers (AMF) on March 22, 2013 and available on Nicox's website( and on the AMF's website (

Pre-clinical results on naproxcinod in models of Muscular Dystrophy pr:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NICOX via Thomson Reuters ONE


Nicox Contacts

Gavin Spencer
Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00
Email Contact

Media Relations FTI Consulting

Jonathan Birt
D+44 (0)20 7269 7205
M +44 (0) 7515 597 858
Email Contact

Stephanie Cuthbert
D +44 (0)20 3077 0458
M +44 (0) 7843 080947
Email Contact

Nicox S.A.
Drakkar 2 | Bat D
2405 route des Dolines
CS 10313 | Sophia Antipolis
06560 Valbonne | France
T: +33 (0)4 97 24 53 00
F: +33 (0)4 97 24 53 99


Comment on this story